ArticleJournal of hematopathology2025
Exploring castleman disease in a cohort of hispanic patients: a recognition to its histopathology.
Article in Journal of hematopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Castleman disease is a clinicopathological entity that shares features with hematological, rheumatological, and infectious diseases, making accurate diagnosis essential. The objective of this study is to characterize the clinical and pathological characteristics of CD in a Mexican cohort. A retrospective study was conducted on adult Mexican patients diagnosed with unicentric (UCD) and multicentric (MCD) Castleman disease from 1985 to 2023. Clinical and histopathological characteristics typical of UCD and MCD were observed. POEMS-associated MCD showed a higher relapse rate. The mixed histopathological variant was more prevalent in MCD. Immunohistochemical expression of VEGF-A was elevated in all CD cases. A multidisciplinary diagnostic approach is crucial for accurately categorizing CD. The mixed histopathological variant was more common than previously reported, especially in MCD. Further studies are needed to validate VEGF-A as a biomarker for CD.
Indexed as
Identifiers
40355649What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.